Back to search results

Observational Study of Magenta AI for IVF Oocyte Sorting

This study is looking at whether using an artificial intelligence (AI) tool called MagentaTM can improve the chances of a successful pregnancy for people undergoing in vitro fertilization (IVF). MagentaTM helps sort oocytes (egg cells) for group culture, which is when eggs are grown together in the lab. Researchers want to see if using MagentaTM leads to more usable blastocysts (early-stage embryos) and ultimately, more pregnancies. You might be able to join if you are undergoing an IVF cycle using your own or donor eggs and sperm, and have fresh mature oocytes. The study will compare how well blastocysts develop over 5 to 7 days. The current status of this study is unclear.

Study design
This is an observational study planning to include 450 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures blastocyst development rate at 5 to 7 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06521372

The Aim of This Study is to Determine if Oocyte Sorting for Group Culture Using an Artificial Intelligence Image Analysis Tool (MagentaTM) Increases the Usable Blastocyst Yield and Subsequent Pregnancy in Patients Undergoing IVF

Recruiting
Not specifiedAll AgesObservational
Ovation Fertility
~450 participants
Updated 2024-07-26 on ClinicalTrials.gov
What's tested:Magenta AI image analysis tool

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Compare blastocyst development rate
Measured over 5 to 7 days

Conditions

Infertility Primary

Explore related trials

Infertility

Where it's being run

3 sites across 3 states
Nevada1
Ohio1
Tennessee1

Who to contact

Matthew VerMilyea, PhD
[email protected]
512-980-0310
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Fresh MII oocytes
ICSI cycles with patient's or donor's sperm
Patient's or donor's oocytes
Full IVF cycle information available (including total number of oocytes retrieved, total MII oocytes, fertilization, embryo and blastocyst development, as well as ploidy status or implantation results, and 6-7 week ultrasound, if applicable)
Good quality images of MII oocytes taken with a specified camera (Basler) and Future Fertility Software
Single embryo transfers (SETs) at blastocyst stage.
Blastocyst freeze-all cycles

Exclusion

Severe male factor infertility (\<1 million motile), including surgically retrieved sperm.
ICSI cycles inseminating in vitro matured (IVM) oocytes
Rescue ICSI oocytes (oocytes failed standard IVF and are re-inseminated by ICSI)
Low quality images - Poor quality images on day of upload or before unblinding
Lack of correlating reproductive outcomes (full IVF lab results not available).
Autologous or donor frozen/warmed oocytes
Day 3 embryo transfers or cleavage stage embryo freezing
Patients with less than 6 mature oocytes

What this trial measures

  • Compare blastocyst development rate5 to 7 days

    Blast Development rates between oocytes (and resulting embryos) that are group cultured according to MagentaTM scores versus oocytes (and resulting embryos group) cultured as per the standard of care following random sorting. Blastocyst development is defined by an embryologist's grading, according to the laboratory's grading system.